Last update:

Weight management news

Is poor sleep contributing to the country's weight issues?

Some 70% of teens trying to adapt to a fall schedule are missing out on sleep. Early bells and tough classes combine with delayed biological clocks during adolescence, keeping their nightly sleep duration during the school ...

GLP-1 use among young children with obesity in US remains rare but is rising rapidly

Although the number of U.S. children under age 12 with obesity who are prescribed the weight-loss drugs Saxenda, Wegovy and Zepbound remains low, it was 310 times higher in June 2026 than in 2019, when the drugs were first ...

Some hair loss in men is linked to weight loss drug use

Men already genetically at risk for the most common form of hair loss have a 7% added risk of losing their hair if they use drugs like Ozempic, Wegovy and Zepbound for type 2 diabetes and obesity, a new study shows.

Why men can struggle with weight-loss initiatives

A new study has identified why many men struggle with weight loss, finding that traditional diet programs are often perceived as too restrictive and primarily aimed at women. The research, published in PLOS One and led by ...

GLP-1 meds prompt rethink of obesity and eating disorder care

Obesity and eating disorders have traditionally been treated as separate areas of health care—but the rapid rise of GLP-1 medicines is increasingly bringing the two together. Adelaide University researchers say the growing ...

Excess belly fat linked to faster biological aging

New research suggests that higher levels of visceral fat, the fat stored deep in the abdomen, could contribute to faster biological aging in middle-aged adults. Adjunct Associate Professors Jennie Hui and Kun Zhu, from The ...

Will GLP-1s lead to fewer prescriptions for older adults?

As people age, they often develop chronic conditions, many of which need to be managed with multiple prescription medications. While medications are important for disease management, polypharmacy poses an increased risk for ...

New oral GLP-1 drug delivers up to 12% weight loss in 36 weeks

A new strategy for delivering GLP-1 drugs to patients with obesity or who were overweight resulted in up to a 12% reduction in body weight after 36 weeks, according to a randomized phase II clinical trial published in Nature ...

'Food noise' discussion on social media helps define the term

With the rise of weight-loss drugs such as GLP-1 medications in recent years, the phrase "food noise" has taken off, particularly in conversations about health and wellness on social media. While thinking about food during ...

Can't stick to a diet? Try intermittent fasting for weight loss

Yo-yo dieters who struggle to lose weight and keep it off may achieve better results by following an intermittent fasting diet, rather than traditional calorie counting. An Adelaide University study focusing on the psychological ...

Why weight‑loss drugs don't work for some people

Weight-loss jabs are the latest craze for shedding a few pounds. Their effect has been dramatic, with drugs such as Ozempic and Wegovy (semaglutide) causing users to lose up to 15% of their body fat on average.

Beyond GLP-1s: The next chapter of obesity care

The rapid rise of GLP-1 medications such as semaglutide and tirzepatide has transformed obesity treatment. Still, experts say medications alone are not enough to address one of the nation's most pressing chronic diseases.

An economic case for teen weight-loss surgery

Metabolic and bariatric surgery for teens with severe obesity was found to be cost-effective over 10 years, according to a new analysis from Ann & Robert H. Lurie Children's Hospital of Chicago published in JAMA Network Open. ...